Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide is a synthetic small molecule with the molecular formula C19H28N4O2 and a molecular weight of approximately 344.5 g/mol[3][8]. It is classified as an experimental compound and has not been approved for clinical use in any jurisdiction[2][3][4]. The compound is structurally related to peptidomimetic inhibitors, but there are no published indications, clinical trials, or detailed pharmacological data available for this molecule. Its mechanism of action and therapeutic targets have not been established in the literature or major drug databases as of June 2025[2][3][4].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(4-carbamimidoylbenzyl)-1-(4-methylpentanoyl)-L-prolinamide.